NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
NextCure, Inc. in partnership with Simcere Zaiming Pharmaceutical have initiated the dose optimization phase of their Phase 1 clinical trial for SIM0505, an antibody drug conjugate targeting cadherin-6 for treating platinum-resistant ovarian cancer. SIM0505 has received Fast Track designation from the FDA, and the companies are expanding their clin…